Skip to main content

COVID-19: Nigeria to take delivery of 3.92 doses of Astrazeneca vaccine

COVID-19: Nigeria to take delivery of 3.92 doses of Astrazeneca vaccine


Nigeria has been scheduled to take delivery of 3.92 million doses of AstraZeneca COVID-19 vaccine.

This was made known in a joint statement  by the World Health Organisation (WHO), United Nations Children’s Fund (UNICEF) and National Primary Health Care Development Agency (NPHCDA) on Sunday in Abuja.

The News Agency of Nigeria (NAN) reports that the country was earlier set to receive its first four million doses of COVID-19 vaccine from COVAX Facility, a global scheme to procure and distribute inoculations for free.

READ ALSO>>>We’re on mission to increase capacity in wheat production — Nanono

 

The COVAX Facility is co-led by Gavi, the Vaccine Alliance, WHO and the Coalition for Epidemic Preparedness Innovations, with UNICEF as a key implementing partner.

It was launched in April 2020 to help ensure a fairer distribution of coronavirus vaccines between rich and poor nations.

COVAX  said it would deliver two billion doses  to its members by the end of 2021.

According to the statement signed by WHO, UNICEF and NPHCDA, the delivery of 3.92 million doses of AstraZeneca COVID-19 vaccine would mark the first arrival of COVID-19 vaccine in Nigeria.

It would also make Nigeria the next West African country to benefit from the COVAX Facility after Ghana and Cote d’Ivoire.

“The arrival of the vaccine will enable the NPHCDA to commence vaccination of Nigerians in priority groups, starting with frontline healthcare workers,  the statement quoted Dr Faisal Shuaib, Executive Director and Chief Executive of NPHCDA, as saying.

The statement also quoted Shuaib as saying that  arrival of the vaccine would be a result of the commitment of the Federal Government,  support of the Presidential Task Force on COVID-19 and guidance of the  Minister of Health, Dr Osagie Ehanire.

“We are fully prepared to receive and deliver the vaccine to eligible Nigerians, as we have commenced training of health workers and ensured that cold chain facilities are ready at all levels.

“We have a robust cold chain system that can store all types of COVID-19 vaccine in accordance with the required temperature.

“We are, therefore, confident that we will have a very effective roll-out of the vaccine, starting with our critical healthcare workers, who are in the frontline in providing the care we all need.”

The statement said that the doses of AstraZeneca vaccine were part of an overall 16 million doses planned to be delivered to Nigeria in batches over the next months by the COVAX Facility as part of an unprecedented global effort to ensure equitable access to COVID-19 vaccines.

“The COVAX Facility has worked exceptionally hard to ensure that Nigeria gets the vaccine as soon as possible so it can start its vaccination programme to the largest population in Africa,” it quoted  Peter Hawkins, UNICEF Nigeria Country Representative, as saying.

According to the statement, vaccines are a critical tool in the battle against COVID-19.

“In the meantime, Nigerians must continue to take steps to contain the virus, as the vaccination programme will take at least a year before it is fully effective,”  the statement quoted Dr Walter Kazadi Mulombo, WHO Representative in Nigeria, as saying.

NAN reports that Nigeria plans to vaccinate at least 70 per cent of the citizens, aged 18 years and above, in four phases within two years.

 

Vanguard News Nigeria 

The post COVID-19: Nigeria to take delivery of 3.92 doses of Astrazeneca vaccine appeared first on Vanguard News.


by David O Royal via Vanguard News https://ift.tt/2O4svzj Best Known Member of the Cabinet Wikipedia

Comments

Popular posts from this blog

Effective Data Governance: IIM-Africa inks partnership deal with Data Management University

President/Chairman of the governing council of IIM-Africa, Dr. Oyedokun Oyewole has said that effective data governance strategy has become more essential for the survival and sustenance of government and businesses, especially with the sudden outbreak of COVID-19 Pandemic. Oyewole said there is the need to ensure that the right policies, processes, technology, and people are in place to effectively manage data while complying with legal and regulatory requirements. He said that as part of the IIM Africa’s commitments towards ensuring global best practices, it has entered into a long-term partnership with DataManagementU.com to bring the finest data management training to industries across Africa. READ ALSO:  COVID-19: Foreign affairs minister says first set of Nigerians abroad to be evacuated soon According to the IIM President, the alliance is expected to provide members of the Institute and other professionals across Africa, high standards, internationally-recognized learn...

Naomi Osaka’s statement about withdrawing from French Open

Japan’s Naomi Osaka returns the ball to Romania’s Patricia Maria Tig during their first round match of the French open tennis tournament at the Roland Garros stadium Sunday, May 30, 2021 in Paris. (AP Photo/Christophe Ena) Naomi Osaka tweeted the following statement announcing her withdrawal from the French Open on Monday: “Hey everyone, this isn’t a situation I ever imagined or intended when I posted a few days ago. I think now the best thing for the tournament, the other players and my well-being is that I withdraw so that everyone can get back to focusing on the tennis going on in Paris. ”I never wanted to be a distraction and I accept that my timing was not idea and my message could have been clearer. ”More importantly I would never trivialize mental health or use the term lightly. The truth is that I have suffered long bouts of depression since the US Open in 2018 and I have had a really hard time coping with that. Anyone that knows me knows I’m introverted, and anyone tha...

Remdesivir: The COVID-19 drug helping patients recover faster

A vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States. PHOTO: AP Remdesivir has been shown to speed up recovery times for patients with COVID-19 in a major US-led trial, becoming the first drug with proven benefit against the disease. Here is what you need to know. – What is remdesivir? – Remdesivir is an experimental, broad spectrum antiviral made by US pharmaceutical Gilead Sciences that was first developed to treat Ebola, a viral hemorrhagic fever. It showed early promise in a primate study in 2016 and was later rolled out for a major trial in the Democratic Republic of Congo, where it was compared against three other medicines. That study concluded in 2019 when it was discontinued because it did not boost survival rates as greatly as two monoclonal antibody drugs, which are lab-engineered immune system proteins. In February, the US National Institute of Allergy and Infectious Diseases (NIAID) announced ...